Skip to Content

Zynquista Approval Status

FDA Approved: No (Pending Approval)
Brand name: Zynquista
Generic name: sotagliflozin
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 1

Zynquista (sotagliflozin) is an investigational dual SGLT1 and SGLT2 inhibitor for use in combination with insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus.

Development Status and FDA Approval Process for Zynquista

DateArticle
Jan 17, 2019FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
May 22, 2018FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
Mar 26, 2018Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes
Dec 21, 2016Lexicon Reports Positive Top-Line Results in Second Pivotal Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes
Sep  9, 2016Lexicon Reports Positive Top-Line Results in Pivotal Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes
Nov  6, 2015Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People With Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide